Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose acetylsalicylic acid for prevention of adverse outcomes in SARS-CoV-2 infected pregnant women
2022-000535-23Phase 3Completed
- Sponsor
- Barcelona Institute for Global Health
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of aspirin in coronavirus disease 2019 (COVID-19), sponsored by Barcelona Institute for Global Health. Primary endpoint: Composite adverse maternal and perinatal outcome. Started Jun 2022; status: completed.
02
Drugs
aspirin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-000535-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000535-23.